Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Front Pharmacol
2022 Jan 01;13:977440. doi: 10.3389/fphar.2022.977440.
Show Gene links
Show Anatomy links
Apamin structure and pharmacology revisited.
Kuzmenkov AI
,
Peigneur S
,
Nasburg JA
,
Mineev KS
,
Nikolaev MV
,
Pinheiro-Junior EL
,
Arseniev AS
,
Wulff H
,
Tytgat J
,
Vassilevski AA
.
???displayArticle.abstract???
Apamin is often cited as one of the few substances selectively acting on small-conductance Ca2+-activated potassium channels (KCa2). However, published pharmacological and structural data remain controversial. Here, we investigated the molecular pharmacology of apamin by two-electrode voltage-clamp in Xenopus laevis oocytes and patch-clamp in HEK293, COS7, and CHO cells expressing the studied ion channels, as well as in isolated rat brain neurons. The microtitre broth dilution method was used for antimicrobial activity screening. The spatial structure of apamin in aqueous solution was determined by NMR spectroscopy. We tested apamin against 42 ion channels (KCa, KV, NaV, nAChR, ASIC, and others) and confirmed its unique selectivity to KCa2 channels. No antimicrobial activity was detected for apamin against Gram-positive or Gram-negative bacteria. The NMR solution structure of apamin was deposited in the Protein Data Bank. The results presented here demonstrate that apamin is a selective nanomolar or even subnanomolar-affinity KCa2 inhibitor with no significant effects on other molecular targets. The spatial structure as well as ample functional data provided here support the use of apamin as a KCa2-selective pharmacological tool and as a template for drug design.
FIGURE 1. Analytical RP-HPLC of apamin and its structure in solution. (A) 10 nmol of peptide was injected onto a Vydac C18 column (4.6 × 250 mm). Reflector-mode MALDI mass spectrum with an isotopic resolution of the purified peptide is shown in the inset. (B) Amino acid sequence of apamin. The numbering is shown above. Amino acid residues are colored with respect to their chemical properties: positively charged residues are shown in blue, negatively charged in red, hydrophobic in green, hydrophilic uncharged in magenta, and cysteines in yellow. Disulfide bridges are shown with lines. (C) A set of 10 NMR structures with the fewest restraint violations (PDB ID: 7OXF). Disulfide bridges are colored in yellow and labeled. (D) The spatial structure of apamin is shown in a ribbon representation. The ɑ-helix is colored pink, and the rest of the main chain is gray. Side chains of the peptide are labeled and colored, the coloring is as in panel (B). Disulfide bridges are shown as yellow sticks.
FIGURE 2. Apamin effects on KCa channels expressed in HEK293 or COS7 cells (in the case of KCa2.3). (A) Effect of increasing concentrations of apamin (10 nM and 500 nM in red and blue, respectively) on KCa2.1 currents. Note that the currents visible above 0 mV are carried by endogenous KV channels in HEK cells. (B) Effect of increasing concentrations of apamin (75 pM and 100 nM in red and blue, respectively) on KCa2.2 currents. (C) Effect of increasing concentrations of apamin (20 nM and 500 nM in red and blue, respectively) on KCa2.3 currents. (D) Concentration-response curves for KCa2.1 (in dark purple), KCa2.2 (teal), and KCa2.3 (red). Data points are mean ± SD from five independent measurements per concentration. (E) KCa3.1 currents (in black) are insensitive to 5 µM apamin (red) but are potently blocked by 1 µM TRAM-34 (blue). (F) KCa1.1 currents evoked by depolarization steps to +80 mV (in black) are insensitive to 5 µM of apamin (red).
FIGURE 3. Electrophysiological profiling of apamin. Shown are representative traces of currents through the corresponding ion channels in control (gray) and after application of 5 μM toxin (blue). In the case of nAChR, TRPV1, and GIRK1/2, blue bars indicate apamin application. In nAChR, arrows indicate agonist (ACh) application. In TRPV1, the open bar shows agonist (capsaicin, CAP) application, and gray bar, antagonist (capsazepine, CZP) application. In GIRK1/2, presentation of different bath solutions is shown as line segments. In ASIC traces, application of the activating pH is shown with gray bars. And in GluR traces, gray bars depict the application of agonists. CaImp, Ca2+-impermeable; CaP, Ca2+-permeable.
Figure S1. Experimental data used for the structure determination of apamin. The following parameters are listed top down: protein sequence with S-S-bonds, NOE connectivities (dij), and 3JHNHA couplings. Widths of the bars represent the relative intensity of cross-peaks in NOESY spectra. Squares have three colors according to the value of J-coupling: black (>8 Hz), gray (6–8 Hz), and white (<6 Hz).
Figure S2. Absolute NMDA current amplitudes in control and in the present of 5μM apamin.
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels.
2021, Pubmed
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels.
2021,
Pubmed
Anthis,
Sequence-specific determination of protein and peptide concentrations by absorbance at 205 nm.
2013,
Pubmed
BEAVEN,
Ultraviolet absorption spectra of proteins and amino acids.
1952,
Pubmed
Banks,
Apamin blocks certain neurotransmitter-induced increases in potassium permeability.
1979,
Pubmed
Barhanin,
Electrophysiological characterization, solubilization and purification of the Tityus gamma toxin receptor associated with the gating component of the Na+ channel from rat brain.
1983,
Pubmed
Bkaily,
Apamin, a highly potent blocker of the TTX- and Mn2(+)-insensitive fast transient Na+ current in young embryonic heart.
1991,
Pubmed
Bkaily,
Apamin, a highly potent fetal L-type Ca2+ current blocker in single heart cells.
1992,
Pubmed
Bkaily,
Apamin, a highly specific Ca2+ blocking agent in heart muscle.
1985,
Pubmed
Buldakova,
Characterization of AMPA receptor populations in rat brain cells by the use of subunit-specific open channel blocking drug, IEM-1460.
1999,
Pubmed
Burgess,
Effects of quinine and apamin on the calcium-dependent potassium permeability of mammalian hepatocytes and red cells.
1981,
Pubmed
Bystrov,
Solution spatial structure of apamin as derived from NMR study.
1980,
Pubmed
Callewaert,
The disulphide bridges of apamin.
1968,
Pubmed
Chen,
Small and intermediate conductance Ca(2+)-activated K+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum.
2004,
Pubmed
Curtis,
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.
2018,
Pubmed
Feranchak,
Calcium-dependent regulation of secretion in biliary epithelial cells: the role of apamin-sensitive SK channels.
2004,
Pubmed
Foster,
Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation.
2010,
Pubmed
Garcia,
Use of toxins to study potassium channels.
1991,
Pubmed
Grunnet,
Apamin interacts with all subtypes of cloned small-conductance Ca2+-activated K+ channels.
2001,
Pubmed
,
Xenbase
Grunnet,
Pharmacological modulation of SK3 channels.
2001,
Pubmed
Güntert,
Torsion angle dynamics for NMR structure calculation with the new program DYANA.
1997,
Pubmed
Habermann,
Apamin.
1984,
Pubmed
Habermann,
Bee and wasp venoms.
1972,
Pubmed
Habermann,
Neurotoxicity of apamin and MCD peptide upon central application.
1977,
Pubmed
Habermann,
[On the biochemistry of bee venom peptides, melittin and apamin].
1965,
Pubmed
Hanke,
Reconstitution of highly purified saxitoxin-sensitive Na+-channels into planar lipid bilayers.
1984,
Pubmed
Hartshorne,
Purification of the saxitoxin receptor of the sodium channel from rat brain.
1981,
Pubmed
Haux,
[Sequence analysis of bee venom neurotoxin (apamine) from its tryptic and chymotryptic cleavage products].
1967,
Pubmed
Herrera,
Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SK3) channel.
2003,
Pubmed
Herzig,
Animal toxins - Nature's evolutionary-refined toolkit for basic research and drug discovery.
2020,
Pubmed
Ishii,
Determinants of apamin and d-tubocurarine block in SK potassium channels.
1997,
Pubmed
,
Xenbase
Jin,
A novel high-affinity inhibitor for inward-rectifier K+ channels.
1998,
Pubmed
,
Xenbase
Koradi,
MOLMOL: a program for display and analysis of macromolecular structures.
1996,
Pubmed
Kuzmenkov,
Diversity of Potassium Channel Ligands: Focus on Scorpion Toxins.
2015,
Pubmed
Kuzmenkov,
Kalium: a database of potassium channel toxins from scorpion venom.
2016,
Pubmed
Kuzmenkov,
Labelled animal toxins as selective molecular markers of ion channels: Applications in neurobiology and beyond.
2018,
Pubmed
Köhler,
Small-conductance, calcium-activated potassium channels from mammalian brain.
1996,
Pubmed
,
Xenbase
Labbé-Jullié,
Binding and toxicity of apamin. Characterization of the active site.
1991,
Pubmed
Lamy,
Allosteric block of KCa2 channels by apamin.
2010,
Pubmed
Lazdunski,
Apamin, a neurotoxin specific for one class of Ca2+-dependent K+ channels.
1983,
Pubmed
Le-Nguyen,
Role of Asn(2) and Glu(7) residues in the oxidative folding and on the conformation of the N-terminal loop of apamin.
NULL,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Narahashi,
Tetrodotoxin: a brief history.
2008,
Pubmed
Nolting,
An amino acid outside the pore region influences apamin sensitivity in small conductance Ca2+-activated K+ channels.
2007,
Pubmed
Pease,
Solution structure of apamin determined by nuclear magnetic resonance and distance geometry.
1988,
Pubmed
Pedarzani,
Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons.
2002,
Pubmed
Peigneur,
Small cyclic sodium channel inhibitors.
2021,
Pubmed
,
Xenbase
Pennefather,
Two distinct Ca-dependent K currents in bullfrog sympathetic ganglion cells.
1985,
Pubmed
Raghuraman,
Melittin: a membrane-active peptide with diverse functions.
2007,
Pubmed
Romey,
The coexistence in rat muscle cells of two distinct classes of Ca2+-dependent K+ channels with different pharmacological properties and different physiological functions.
1984,
Pubmed
Sabatier,
Leiurotoxin I, a scorpion toxin specific for Ca(2+)-activated K+ channels. Structure-activity analysis using synthetic analogs.
1994,
Pubmed
Sabatier,
P05, a new leiurotoxin I-like scorpion toxin: synthesis and structure-activity relationships of the alpha-amidated analog, a ligand of Ca(2+)-activated K+ channels with increased affinity.
1993,
Pubmed
Sandberg,
Solid phase synthesis of 13-lysine-apamin, 14-lysine-apamin and the corresponding guanidinated derivatives.
1979,
Pubmed
Sankaranarayanan,
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
2009,
Pubmed
Seifert,
Developmental regulation of AMPA-receptor properties in CA1 pyramidal neurons of rat hippocampus.
2000,
Pubmed
Shah,
The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines.
2000,
Pubmed
,
Xenbase
Shakkottai,
Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
2001,
Pubmed
Skibsbye,
Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria.
2014,
Pubmed
Stocker,
Differential distribution of three Ca(2+)-activated K(+) channel subunits, SK1, SK2, and SK3, in the adult rat central nervous system.
2000,
Pubmed
Strassmaier,
A novel isoform of SK2 assembles with other SK subunits in mouse brain.
2005,
Pubmed
Strøbaek,
Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
2000,
Pubmed
Tabakmakher,
Kalium 2.0, a comprehensive database of polypeptide ligands of potassium channels.
2019,
Pubmed
Tamarina,
Small-conductance calcium-activated K+ channels are expressed in pancreatic islets and regulate glucose responses.
2003,
Pubmed
Tuteja,
Differential expression of small-conductance Ca2+-activated K+ channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes.
2005,
Pubmed
Vassilevski,
Purification and characterization of biologically active peptides from spider venoms.
2010,
Pubmed
Vassilevski,
Molecular diversity of spider venom.
2009,
Pubmed
Vincent,
Structure-function relationships and site of action of apamin, a neurotoxic polypeptide of bee venom with an action on the central nervous system.
1975,
Pubmed
Voos,
The small neurotoxin apamin blocks not only small conductance Ca2+ activated K+ channels (SK type) but also the voltage dependent Kv1.3 channel.
2017,
Pubmed
Vorobjev,
Vibrodissociation of sliced mammalian nervous tissue.
1991,
Pubmed
Weatherall,
Crucial role of a shared extracellular loop in apamin sensitivity and maintenance of pore shape of small-conductance calcium-activated potassium (SK) channels.
2011,
Pubmed
Wemmer,
Structure of apamin in solution: a two-dimensional nuclear magnetic resonance study.
1983,
Pubmed
Weng,
Cell type-specific expression of acid-sensing ion channels in hippocampal interneurons.
2010,
Pubmed
Wenthold,
Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons.
1996,
Pubmed
Wulff,
Antibodies and venom peptides: new modalities for ion channels.
2019,
Pubmed
Wulff,
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.
2000,
Pubmed
Xia,
Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
1998,
Pubmed
,
Xenbase
Xu,
Molecular identification and functional roles of a Ca(2+)-activated K+ channel in human and mouse hearts.
2003,
Pubmed
Yu,
Apamin does not inhibit human cardiac Na+ current, L-type Ca2+ current or other major K+ currents.
2014,
Pubmed
Zeisel,
Molecular Architecture of the Mouse Nervous System.
2018,
Pubmed